Immunohistochemical detection of dopamine D2 receptors in human pituitary adenomas

Folia Histochemica et Cytobiologica

Volumn 48, Issue 3, 2010, Pages 394-397

  Pawlikowski, Marek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Angiogenesis; D2 receptors; Dopamine; Immunohistochemistry; Pituitary adenomas

Indexed keywords

DOPAMINE 2 RECEPTOR;

ACROMEGALY; ACTH SECRETING ADENOMA; ARTICLE; CELL NUCLEUS; CELL SUBPOPULATION; CLINICAL ARTICLE; CYTOPLASM; GONADOTROPH ADENOMA; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PHENOTYPE; PLURIHORMONAL ADENOMA; PROLACTINOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

EID: 78649599327     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-010-0031-1     Document Type: Article

References (19)

1. Shaar CJ, Clemens JA. The role of catecholamines in the release of anterior pituitary prolactin in vitro. Endocrinology. 1974;95:1202-1212.
2. MacLeod RM, Lehmeyer JE. Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Endocrinology. 1974;94:1077-1085.
3. Pawlikowski M, Kunert-Radek J, Stepien H. Direct antiproliferative effect of dopamine agonists on the pituitary gland in organ culture. J Endocr. 1978;79:245-246.
4. Pivonello R, Ferone D, Lombardi G et al. Novel insights in dopamine receptor physiology. Eur J Endocrinol. 2007; 156(supl.1):S13-S21.
5. Fluckiger E, Wagner HR. 2-Br-alpha ergocryptin beinflussung von fertilitat und lactation bei der ratte. Experientia. 1968;24:1130-1131.
6. Casanueva FF, Molitch ME, Schlechte JA et al. Guidelines of the Pituitary Society for the diagnosis and treatment of prolactinomas. Clin Endocrinol (Oxf). 2006;65:265-273.
7. Benker G, Zah W, Hackenberg K et al. Long -term treatment of acromegaly with bromocryptine: postprandial HGH levels and response to TRH and glucose administration. Horm Metab Res. 1976;8:291-295.
8. Ferone D, Pivonello R, Resmini E et al. Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas. Eur J Endocrinol. 2007;156 (supl.1):S37-S43.
9. Saveanu A, Lavaque E, Gunz C et al. Demonstration of enhanced potency of a chimeric somatostatin/dopamine molecule BIM 23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab. 2002;87:5545-5552.
10. Gruszka A, Kunert-Radek J, Radek A et al. The effect of selective sst1,sst2,sst5 somatostatin receptor agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on clinically non-functioning pituitary adenomas in vitro. Life Sci. 2006;78:689-693.
11. Wang H. Dopamine D2 receptors are present in prefrontal cortical afferents and their targets in patches of the rat caudate - putamen nucleus. J Comparative Neurology. 2002;442:392-404.
12. Mengual E, Pickel V. Ultrastructural immunocytochemical localization of the dopamine D2 receptor and tyrosine hydroxylase in the rat ventral pallidum. Synapse. 2002;43: 151-162.
13. Pawlikowski M, Gruszka A, Kurnatowska I et al. Proliferating cell nuclear antigen (PCNA) expression in pituitary adenomas: relationship to the endocrine phenotype of adenoma. Folia Histochem Cytobiol. 2006;44:37-41.
14. Ferone D, de Herder W, Pivonello R et al. Correlation of in vitro and in vivo somatostropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocr Metab. 2008;93:1412-1417.
15. Pivonello R. Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocr Metab. 2004;89:2452-2462.
16. Stefaneanu L, Kovacs K, Horvath E et al. Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine. 2001;14:329-330.
17. Pivonello R, Matrone C, Filipella M et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocr Metab. 2004;89:1647-1648.
18. Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S. Catecholamines regulate tumor angiogenesis. Cancer Res. 2009; 69:3727-3730.
19. Basu S, Sarkar C, Chakroborty D et al. Ablation of peripheral dopaminegic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor - mediated angiogenesis. Cancer Res. 2004;64:5551-5555.